Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) methylergonovine (HOS-086155) propafenone (HOS-084530) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-086278 · Präparat HOS-083284
Antipsychotics/Neuroleptics
Clozapine, pimozide Ritonavir co-administration is likely to result in increased plasma concentrations of
clozapine or pimozide and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) clozapine (HOS-086149)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9b673d4bcfd59f47bb6c54c40be4618c80a44972f74bc511b794d09c8b64bb1 · Zeichen 37523–37792 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-086458 · Präparat HOS-083284
Antipsychotics/Neuroleptics
Clozapine, pimozide Ritonavir co-administration is likely to result in increased plasma concentrations of
clozapine or pimozide and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) clozapine (HOS-086149)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9b673d4bcfd59f47bb6c54c40be4618c80a44972f74bc511b794d09c8b64bb1 · Zeichen 39314–39583 im Abschnitt
Wechselwirkungen · Insuman
Insuman Rapid 40 IU/ml solution for injection in a vial Insuman Rapid 100 IU/ml solution for injection in a vial · Abschnitt 4.5 · PDF-Seite 6
HOS-088587 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 500–945 im Abschnitt
Wechselwirkungen · Insuman
Insuman Rapid 100 IU/ml solution for injection in a cartridge Insuman Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 16
HOS-088613 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 445–890 im Abschnitt
Wechselwirkungen · Insuman
Insuman Basal 40 IU/ml suspension for injection in a vial Insuman Basal 100 IU/ml suspension for injection in a vial Insuman Basal 100 IU/ml suspension for injection in a cartridge Insuman Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 27
HOS-088633 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 446–891 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 15 100 IU/ml suspension for injection in a vial Insuman Comb 15 100 IU/ml suspension for injection in a cartridge Insuman Comb 15 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 39
HOS-088652 · Präparat HOS-083671
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) pentoxifylline (HOS-088586) disopyramide (HOS-085595) danazol (HOS-085473) fluoxetine (HOS-085946) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 18919877bb39ad0d4ea769fe50ee0dec48b2e438f4ee9db39eb8acbd3926e791 · Zeichen 100–890 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 25 40 IU/ml suspension for injection in a vial Insuman Comb 25 100 IU/ml suspension for injection in a vial Insuman Comb 25 100 IU/ml suspension for injection in a cartridge Insuman Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 51
HOS-088671 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 446–891 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 30 100 IU/ml suspension for injection in a vial Insuman Comb 30 100 IU/ml suspension for injection in a cartridge Insuman Comb 30 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 64
HOS-088691 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 446–891 im Abschnitt
Wechselwirkungen · Insuman
Insuman Comb 50 40 IU/ml suspension for injection in a vial Insuman Comb 50 100 IU/ml suspension for injection in a vial Insuman Comb 50 100 IU/ml suspension for injection in a cartridge Insuman Comb 50 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 76
HOS-088710 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 446–891 im Abschnitt
Wechselwirkungen · Insuman
Insuman Infusat 100 IU/ml solution for injection in a vial · Abschnitt 4.5 · PDF-Seite 88
HOS-088729 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the
blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycaemia which may
sometimes be followed by hyperglycaemia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) clonidine (HOS-088594) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) pentamidine (HOS-085605) lithium (HOS-085952) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 0831a46f4a9d9c3e85834be7a34c80f022f5f35ea7a7d496eecd25cd128c0bc9 · Zeichen 501–1162 im Abschnitt
Wechselwirkungen · Insuman
Insuman Implantable 400 IU/ml solution for infusion · Abschnitt 4.5 · PDF-Seite 99
HOS-088750 · Präparat HOS-083671
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 299e429ac3daeb179a69266723aef3984cf10eeefd3c2062efd740c9f51d4c1c · Zeichen 446–891 im Abschnitt
Wechselwirkungen · Lantus
Lantus 100 units/ml solution for injection in a vial Lantus 100 units/ml solution for injection in a cartridge Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 6
HOS-091009 · Präparat HOS-084169
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives,
somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and
olanzapine) and protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T11:08:00Z · SHA-256 675b799bf0c080ebd4fa5597f08423cd1cb573541330b2cc6a5cdd808c8fe620 · Passage 61284a14fb69191ebce9b83a217b45d4e23027f634a07f4ef6ee4570280b9574 · Zeichen 448–863 im Abschnitt
Wechselwirkungen · Toujeo (previously Optisulin)
Toujeo 300 units/ml SoloStar, solution for injection in a pre-filled pen Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 7
HOS-091279 · Präparat HOS-084253
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives,
somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and
olanzapine) and protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T16:06:00Z · SHA-256 05d36a6d50acda15612619f58c6f2b433b88d383f261fed3243417274c24906d · Passage 61284a14fb69191ebce9b83a217b45d4e23027f634a07f4ef6ee4570280b9574 · Zeichen 450–865 im Abschnitt
Wechselwirkungen · Kentera (previously Oxybutynin Nicobrand)
Kentera 3.9 mg / 24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 4
HOS-112665 · Präparat HOS-093719
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or
medicinal products with anticholinergic activity, such as amantadine and other anticholinergic
antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g.
phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related
compounds like atropinic antispasmodics, dipyridamole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dipyridamole (HOS-088796) quinidine (HOS-085593) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) clozapine (HOS-086149) levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-08T02:00:00Z · SHA-256 f16314d201d86c4de73d4a8a846ed94a7bcbbf05b4bc16677f6a496640258172 · Passage ae9bf8942659fc6f010d6a4fab9405d48db816ef4526645c80755b03496f6889 · Zeichen 764–1220 im Abschnitt
Wechselwirkungen · Apidra
Apidra 100 Units/ml solution for injection in a vial Apidra 100 Units/ml solution for injection in a cartridge Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 5–6
HOS-113139 · Präparat HOS-093863
5
Substances that may enhance the blood-glucose-lowering activity and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Substances that may reduce the blood-glucose-lowering activity include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic
medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones,
oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the
blood-glucose-lowering activity of insulin. Pentamidine may cause hypoglycaemia, which may
sometimes be followed by hyperglycaemia.
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine,
guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) olanzapine (HOS-085937) protease (HOS-085623) clonidine (HOS-088594) diazoxide (HOS-088588) pentoxifylline (HOS-088586) disopyramide (HOS-085595) danazol (HOS-085473) fluoxetine (HOS-085946) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) pentamidine (HOS-085605) guanethidine (HOS-088596) lithium (HOS-085952) terbutaline (HOS-085475) isoniazid (HOS-088590) reserpine (HOS-088597) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T10:29:00Z · SHA-256 fc7e65813a72a5fb5b10ba10898c4aef13a83c5955dfc98f08190846113082bd · Passage 661b2a3146139e13085dd5957710df1feb005d83c38b437fd29b69c7627db493 · Zeichen 390–1603 im Abschnitt
Wechselwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-115544 · Präparat HOS-094307
Interaction with theophylline and other agents metabolised by CYP1A2
In a healthy volunteer study, the concomitant administration of deferasirox as a CYP1A2 inhibitor
(repeated dose of 30 mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate
theophylline (single dose of 120 mg) resulted in an increase of theophylline AUC by 84% (90% CI:
73% to 95%). The single dose Cmax was not affected, but an increase of theophylline Cmax is expected
to occur with chronic dosing. Therefore, the concomitant use of deferasirox with theophylline is not
recommended. If deferasirox and theophylline are used concomitantly, monitoring of theophylline
concentration and theophylline dose reduction should be considered. An interaction between
deferasirox and other CYP1A2 substrates cannot be excluded. For substances that are predominantly
metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine, tizanidine), the
same recommendations apply as for theophylline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tizanidine (HOS-089668) theophylline (HOS-085910) clozapine (HOS-086149)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 324a30d64741eba975810c0dac305bef3446ac4d5128757173e592b662d8f36f · Zeichen 2559–3543 im Abschnitt
Wechselwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 32
HOS-115575 · Präparat HOS-094307
Interaction with theophylline and other agents metabolised by CYP1A2
In a healthy volunteer study, the concomitant administration of deferasirox as a CYP1A2 inhibitor
(repeated dose of 30 mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate
theophylline (single dose of 120 mg) resulted in an increase of theophylline AUC by 84% (90% CI:
73% to 95%). The single dose Cmax was not affected, but an increase of theophylline Cmax is expected
to occur with chronic dosing. Therefore, the concomitant use of deferasirox with theophylline is not
recommended. If deferasirox and theophylline are used concomitantly, monitoring of theophylline
concentration and theophylline dose reduction should be considered. An interaction between
deferasirox and other CYP1A2 substrates cannot be excluded. For substances that are predominantly
metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine, tizanidine), the
same recommendations apply as for theophylline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tizanidine (HOS-089668) theophylline (HOS-085910) clozapine (HOS-086149)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 324a30d64741eba975810c0dac305bef3446ac4d5128757173e592b662d8f36f · Zeichen 2702–3686 im Abschnitt
Wechselwirkungen · Invega
INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-208670 · Präparat HOS-154161
Caution is advised if paliperidone is combined with other medicines known to lower the seizure
threshold (i.e., phenothiazines or butyrophenones, clozapine, tricyclics or SSRIs, tramadol,
mefloquine, etc.).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clozapine (HOS-086149) mefloquine (HOS-113850) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-12T09:16:00Z · SHA-256 c022336c81d7daff47a10cc72695ac049d82faed32c71ea4b5bbe029107608a3 · Passage a1a6f7ee4b5bc6a1b491ff034c7c5fb1b1330b266f95a0e9f783fbf658deb83f · Zeichen 1298–1504 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.